Abstract: An automated driving system of a vehicle includes a driver monitoring unit configured to perform at least one of monitoring a gaze of a driver and determining a position of a hand of the driver, an automated-driving-level switching unit configured to determine whether a transition of a driving control over the vehicle is required based on whether driving environment of the vehicle has changed during the vehicle being driven under control of the automated driving system, and determine an automated driving level to be switched based on a driver monitoring result obtained by the drive monitoring unit, and an automated driving control unit configured to control the vehicle according to the automated driving level.

Abstract: A method of predicting the risk of experiencing symptoms related to abnormal blood pressure and/or heart rate that includes obtaining subject heart rate variability data representing a number of HRV parameters, wherein the subject HRV data is generated based on heartbeat data obtained from an individual wearing a heart parameter sensor, providing the subject HRV data as an input to an artificial intelligence system, wherein the artificial intelligence system has been previously trained using training and test HRV data representing the number of HRV parameters obtained from a plurality of test subjects, and analyzing temporal data changes in or indicated by the subject HRV data in the artificial intelligence system to determine whether the individual is at risk of experiencing symptoms related to abnormal blood pressure and/or heart rate placing them at risk of a fall.

Abstract: Provided is a pharmaceutical composition including clopidogrel bisulfate and a pregelatinized starch. The pharmaceutical composition in which the stability of clopidogrel bisulfate is significantly enhanced can be obtained by mixing clopidogrel bisulfate with the pregelatinized starch.

Abstract: Disclosed is a multiple unit type sustained release oral formulation comprising sustained release pellets formed from granules containing an active ingredient and a water-insoluble polymer, the granules being coated with a sustained release base material; and rapid release granules containing the active ingredient, and a method for preparing the same.

Abstract: Disclosed is a zaltoprofen-containing sustained release tablet comprising granules containing zaltoprofen and a binder, in which the granules are dispersed in a matrix comprising a hydrophilic polymer, and a diluent is present either in the granules or in the matrix.

Abstract: Disclosed are novel inorganic acid salts of sibutramine, which have good physicochemical properties, and crystalline forms thereof. Also disclosed are pharmaceutical compositions comprising the compounds as effective ingredients, methods of preparing the compounds, and the use of the compounds.

Abstract: Disclosed is a novel sulphonic acid salt of sibutramine, which has good physicochemical properties. Also disclosed are a method of preparing the compound and a pharmaceutical composition comprising the compound.

Abstract: Disclosed is a novel dicarboxylic acid salt of sibutramine, which has good physicochemical properties. Also disclosed are a method of preparing the compound and a pharmaceutical composition comprising the compound.